Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
72 hedge funds and large institutions have $15.9M invested in Asterias Biotherapeutics Inc. Series A in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 75 → 72 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
38% less capital invested
Capital invested by funds: $25.5M → $15.9M (-$9.65M)
55% less call options, than puts
Call options by funds: $106K | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$920K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$208K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$102K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$60.3K |
| 5 |
State Street
Boston,
Massachusetts
|
+$47.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$285K |
| 3 |
Millennium Management
New York
|
-$132K |
| 4 |
VF
Virtu Financial
New York
|
-$77.7K |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$75.1K |
AST Hedge Fund Activity: Q1 2018 in Review
72 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q1 2018, worth a combined $15.9M — down 38% from $25.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AST and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 21 added.
The largest buyer was Vanguard Group, adding an estimated $920K. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.6M sold.
- 72 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q1 2018, down from 75 in Q4 2017.
- Funds reported $15.9M of Asterias Biotherapeutics Inc. Series A stock for Q1 2018, down 38% quarter-over-quarter.
- 7 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q1 2018 and 10 closed out, a net change of -3 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q1 2018 was Vanguard Group, an estimated $920K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q1 2018 was Fidelity Investments, an estimated $1.6M sold.
Based on aggregated 13F filings for Q1 2018.